Cantor Fitzgerald Reiterates Buy Rating, $60 PT on Salix Pharmaceuticals Ltd.
Posted on January 02, 2013 at 13:57 PM EST
In a report published Wednesday, Cantor Fitzgerald reiterated its Buy rating and $60.00 price target on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP ). Cantor Fitzgerald noted, “Management has previously guided to a $150-200M opportunity for this product. We currently model 2013 revenues of $8M, growing to $102M in 2020 (Bloomberg 2013